array(0) { }

Overview

Despite the existence of a number of practice guidelines and a broad range of pharmaceutical treatment options, more than 60% of diabetes mellitus (DM) patients do not reach HBA1c target goals. This unacceptable rate of treatment failure is related to poor adherence to clinical practice guidelines.

This CME program will help to address the above educational gaps among physicians and improve their awareness of the latest practice guidelines and available treatment options, so they can better manage their patients with diabetes.

Faculty

	David Kendall, MD (Chair) Medical Director and Chief of Clinical and Professional Services International Diabetes Center Minneapolis, MN
	Diane Reader, RD, LD, CDE Manager, Diabetes Professional Education International Diabetes Center Minneapolis, MN
	Richard Bergenstal, MD Executive Director International Diabetes Center Minneapolis, MN

Target Audience

This program was developed for endocrinologists, primary care physicians, nurses, diabetes nurses, and diabetes educators.

Educational Objectives

Upon completion of this activity, participants should understand and demonstrate the ability to:

• Describe the health impact of the complications of diabetes mellitus
• Explain the merits of existing treatment options to normalize glycemia
• Through a case study, demonstrate the ability to manage a patient with difficult to control glycemia as indicated in current guidelines and using the available drugs and tools
• Compare and contrast the three major diabetes treatment guidelines

System Requirements

In order to view these presentations, your computer must have:

• Audio capabilities (working speakers or headphones)
• Microsoft Windows Media Player v6.4 or RealPlayer 8 or later. Click here for more information.

Accreditation Statements

The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Medical Education Resources is an approved provider of continuing nursing education by the Colorado Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Credit Designation

The Potomac Center for Medical Education designates this educational activity for a maximum of .75 AMA PRA Category I credit(s)™ per Webcourse Session. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Physicians have the opportunity to earn up to 1.5 AMA PRA Category I credit(s)™ by completing both sessions.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

David Kendall, MD: Speaker: Amylin, Eli Lilly; Consultant: Amylin, Eli Lilly, Takeda; Research Support: Amylin, Eli Lilly, Lifescan, Abbott Laboratories, Novo Nordisk, Sanofi-Aventis

Diane Reader, RD, LD, CDE: Nothing to Disclose

Richard Bergenstal, MD: Research: Amylin, Eli Lilly, LifeScan, MannKind, Medtronic, Novo Nordisk, Sanofi Aventis, ResMed; Advisory Panel: Abbott Diabetes Care, Eli Lilly, Intuity, Mannkind, Medtronic, Metrika, Novo Nordisk, Roche, Sanofi Aventis, Valeritas; Shareholder: Merck

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests: Laurie Frueh, MD; Barry Watkins, PhD; Brad Pine; Donna Fucello; Blair St. Amand; Dana Simpler, MD: Nothing to Disclose

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Supported by an educational grant from

By clicking either of these button, you are agreeing that you have read and understood the CME Statements above.